Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ACW NYSE:BIT NASDAQ:IPA NASDAQ:RZLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACWAccuride$2.58$0.00$0.74▼$2.84N/AN/A350,178 shsN/ABITBlackRock Multi-Sector Income Trust$13.43+0.4%$14.21$12.50▼$15.21N/AN/A235,095 shs952,806 shsIPAImmunoPrecise Antibodies$2.10+8.5%$2.10$0.27▼$3.25$96.68M0.531.83 million shs1.97 million shsRZLTRezolute$8.20+6.4%$6.57$2.21▼$8.34$670.74M0.03898,100 shs2.94 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACWAccuride0.00%0.00%0.00%0.00%0.00%BITBlackRock Multi-Sector Income Trust+0.45%-3.55%-2.90%-6.61%-10.65%IPAImmunoPrecise Antibodies0.00%0.00%-18.48%+108.46%+217.42%RZLTRezolute+6.36%+2.89%+26.74%+99.51%+68.38%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACWAccuride$2.58$0.00$0.74▼$2.84N/AN/A350,178 shsN/ABITBlackRock Multi-Sector Income Trust$13.43+0.4%$14.21$12.50▼$15.21N/AN/A235,095 shs952,806 shsIPAImmunoPrecise Antibodies$2.10+8.5%$2.10$0.27▼$3.25$96.68M0.531.83 million shs1.97 million shsRZLTRezolute$8.20+6.4%$6.57$2.21▼$8.34$670.74M0.03898,100 shs2.94 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACWAccuride0.00%0.00%0.00%0.00%0.00%BITBlackRock Multi-Sector Income Trust+0.45%-3.55%-2.90%-6.61%-10.65%IPAImmunoPrecise Antibodies0.00%0.00%-18.48%+108.46%+217.42%RZLTRezolute+6.36%+2.89%+26.74%+99.51%+68.38%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACWAccuride 0.00N/AN/AN/ABITBlackRock Multi-Sector Income Trust 0.00N/AN/AN/AIPAImmunoPrecise Antibodies 3.00Buy$4.0090.93% UpsideRZLTRezolute 3.17Buy$13.0058.54% UpsideCurrent Analyst Ratings BreakdownLatest RZLT, IPA, BIT, and ACW Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/18/2025RZLTRezoluteWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$12.009/18/2025RZLTRezoluteBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.009/3/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.00(Data available from 9/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACWAccurideN/AN/AN/AN/AN/AN/ABITBlackRock Multi-Sector Income Trust$58.52MN/AN/AN/AN/AN/AIPAImmunoPrecise Antibodies$17.59M5.50N/AN/A$0.37 per share5.66RZLTRezoluteN/AN/AN/AN/A$2.19 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACWAccurideN/AN/A0.00∞N/AN/AN/AN/AN/ABITBlackRock Multi-Sector Income TrustN/AN/A0.00∞N/AN/AN/AN/AN/AIPAImmunoPrecise Antibodies-$21.69M-$0.68N/AN/AN/A-122.10%-40.62%-22.19%12/8/2025 (Estimated)RZLTRezolute-$68.46M-$1.15N/AN/AN/AN/A-75.52%-67.61%N/ALatest RZLT, IPA, BIT, and ACW EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/17/2025Q4 2025RZLTRezolute-$0.23-$0.26-$0.03-$0.26N/AN/A7/29/2025Q4 2025IPAImmunoPrecise Antibodies-$0.02-$0.04-$0.02-$0.04$7.89 million$5.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACWAccurideN/AN/AN/AN/AN/ABITBlackRock Multi-Sector Income Trust$1.4811.02%N/AN/AN/AIPAImmunoPrecise AntibodiesN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ALatest RZLT, IPA, BIT, and ACW DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/20/2025BITBlackRock Multi-Sector Income Trustmonthly$0.123710.89%9/15/20259/15/20259/30/20258/1/2025BITBlackRock Multi-Sector Income Trustmonthly$0.123710.1%8/15/20258/15/20258/29/20257/1/2025BITBlackRock Multi-Sector Income Trustmonthly$0.123710.1%7/15/20257/15/20257/31/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACWAccurideN/AN/AN/ABITBlackRock Multi-Sector Income TrustN/AN/AN/AIPAImmunoPrecise Antibodies0.492.081.85RZLTRezoluteN/A8.438.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACWAccuride46.60%BITBlackRock Multi-Sector Income TrustN/AIPAImmunoPrecise Antibodies6.70%RZLTRezolute82.97%Insider OwnershipCompanyInsider OwnershipACWAccuride2.56%BITBlackRock Multi-Sector Income TrustN/AIPAImmunoPrecise Antibodies6.83%RZLTRezolute18.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACWAccurideN/AN/AN/ANot OptionableBITBlackRock Multi-Sector Income TrustN/AN/AN/ANot OptionableIPAImmunoPrecise Antibodies8046.15 million43.00 millionNot OptionableRZLTRezolute4087.00 million71.00 millionOptionableRZLT, IPA, BIT, and ACW HeadlinesRecent News About These CompaniesRezolute (NASDAQ:RZLT) Earns "Buy" Rating from BTIG Research1 hour ago | americanbankingnews.comRezolute (NASDAQ:RZLT) Posts Earnings Results, Misses Estimates By $0.04 EPSSeptember 18 at 5:14 PM | marketbeat.comRezolute, Inc.: Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business UpdateSeptember 18 at 4:47 AM | finanznachrichten.deRezolute, Inc. Reports Fiscal 2025 Financial ResultsSeptember 17 at 12:11 AM | tipranks.comRezolute reports Q4 EPS (26c), consensus (23c)September 17 at 11:47 PM | msn.comRezolute, Inc. Reports Q4 and Full Year Fiscal 2025 Financial Results and Updates on Ersodetug Development ProgressSeptember 17 at 4:30 PM | quiverquant.comQRezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business UpdateSeptember 17 at 4:05 PM | globenewswire.comRezolute Stock: FDA Fast Track Fuels 2025 Breakout...September 17 at 7:05 AM | marketbeat.comAcadian Asset Management LLC Grows Stake in Rezolute, Inc. $RZLTSeptember 17 at 3:17 AM | marketbeat.comRezolute: FDA Pivotal Trial Alignment Change Further Bolsters ErsodetugSeptember 16 at 4:36 PM | seekingalpha.comRezolute (NASDAQ:RZLT) Stock Price Down 3.6% - Time to Sell?September 16 at 4:32 PM | marketbeat.comRezolute (RZLT) Projected to Post Quarterly Earnings on ThursdaySeptember 16 at 2:11 AM | americanbankingnews.comRezolute (NASDAQ:RZLT) Reaches New 52-Week High - Here's WhySeptember 13, 2025 | marketbeat.comCubist Systematic Strategies LLC Grows Stock Holdings in Rezolute, Inc. $RZLTSeptember 13, 2025 | marketbeat.comRezolute, Inc. (RZLT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 12, 2025 | seekingalpha.comRezolute (RZLT) Expected to Announce Quarterly Earnings on ThursdaySeptember 12, 2025 | marketbeat.comWalleye Capital LLC Decreases Stock Position in Rezolute, Inc. $RZLTSeptember 8, 2025 | marketbeat.comRezolute, Inc. $RZLT Shares Bought by OMERS ADMINISTRATION CorpSeptember 6, 2025 | marketbeat.comRezolute, Inc. (NASDAQ:RZLT) Given Consensus Recommendation of "Buy" by AnalystsSeptember 5, 2025 | marketbeat.comRezolute (NASDAQ:RZLT) Receives "Buy" Rating from HC WainwrightSeptember 5, 2025 | marketbeat.comADAR1 Capital Management LLC Cuts Stock Position in Rezolute, Inc. $RZLTSeptember 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Why BitMine’s Massive Discount Could Signal a Major OpportunityBy Jeffrey Neal Johnson | August 21, 2025Tilray's High Hopes: The Catalyst Driving Cannabis StocksBy Jeffrey Neal Johnson | August 21, 2025Time to Take Profits on Strategy Stock? 3 Reasons You ShouldBy Gabriel Osorio-Mazilli | September 1, 2025Defense Dividends: 3 Strong Performers That Are Raising PayoutsBy Leo Miller | August 29, 2025RZLT, IPA, BIT, and ACW Company DescriptionsAccuride NYSE:ACWAccuride Corporation is a United States-based manufacturer and supplier of wheels, wheel-end components and other products to the North American commercial vehicle industry. The Company's products include steel and aluminum commercial vehicle wheels and assemblies, truck body and chassis parts, and gray, ductile and austempered ductile iron castings. The Company's products are marketed under various brands, such as Accuride Wheel End Solutions (Accuride Wheels and Gunite), Accu-Flange and Gianetti Ruote. The Company uses Steel Armor steel wheel powder coating technology. The Company also offers stud-piloted, tubeless and tube-type forged aluminum wheels, brake drums and disc wheel hubs in commercial vehicles. The Company serves the original equipment manufacturers (OEMs) and their related aftermarket channels. The Company serves the commercial vehicle market, including heavy and medium-duty trucks, commercial trailers, light trucks, buses, and specialty and military vehicles.BlackRock Multi-Sector Income Trust NYSE:BIT$13.43 +0.06 (+0.45%) Closing price 09/18/2025 03:59 PM EasternExtended Trading$13.42 -0.01 (-0.07%) As of 09/18/2025 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BlackRock Multi-Sector Income Trust is a close ended fixed income mutual fund launched by BlackRock, Inc. It is co-managed by BlackRock Advisors, LLC and BlackRock (Singapore) Limited. The fund invests in fixed income markets. It invests primarily in loan and debt instruments and other investments with similar economic characteristic. BlackRock Multi-Sector Income Trust was formed on February 25, 2013 and is domiciled in the United States.ImmunoPrecise Antibodies NASDAQ:IPA$2.10 +0.17 (+8.55%) Closing price 09/3/2025Extended Trading$2.10 0.00 (0.00%) As of 09/3/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.Rezolute NASDAQ:RZLT$8.20 +0.49 (+6.36%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$8.32 +0.13 (+1.52%) As of 09/18/2025 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Bloom Energy Booms on AI Power Demand and Analyst Upgrades Can Apple’s iPhone 17 and AI Push Its Stock to New Highs? Why Seagate Is Wall Street's New Favorite AI Infrastructure Play New Catalysts Build Positive Pressure on Intel Stock Oracle to Hit $1 Trillion Valuation in 2025: Here’s Why General Mills Is a Generational Opportunity for Income Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
